JCI table of contents: March 20, 2008(known as contact inhibition) tumor cells...),Health

Date:3/20/2008

known as contact inhibition), tumor cells do not. New data, generated by Jung Weon Lee and colleagues, at Seoul National University, Republic of Korea, has now indicated that the protein TM4SF5 has a crucial role in the ability of human hepatocarcinoma cells to overcome contact inhibition and grow in an uncontrolled manner.

In the study, TM4SF5 was found to be overexpressed in human hepatocarcinoma tissue. This overexpression mediated cellular effects that caused the tumor cells to undergo a process known as epithelial-mesenchymal transition, and resulted in uncontrolled growth, both in vitro and when the cells were injected into mice. The importance of these data, which imply TM4SF5 has a crucial role in cancer progression, is discussed in an accompanying commentary by Ruth Muschel and Annamaria Gal from the University of Oxford, United Kingdom.

TITLE: Tetraspanin TM4SF5 mediates loss of contact inhibition through epithelial-mesenchymal transition in human hepatocarcinoma

AUTHOR CONTACT:
Jung Weon Lee
Seoul National University, Seoul, Republic of Korea.
Phone: 82-2-3668-7030; Fax: 82-2-766-4487; E-mail: jwl@snu.ac.kr.

View the PDF of this article at: https://www.the-jci.org/article.php?id=33768

ACCOMPANYING COMMENTARY

TITLE: Tetraspanin in oncogenic epithelial-mesenchymal transition

AUTHOR CONTACT:
Ruth J. Muschel
University of Oxford, Oxford, United Kingdom.
Phone: 44-0-1865-857-427; Fax: 44-0-1865-857-533; Email: ruth.muschel@rob.ox.ac.uk.

View the PDF of this article at: https://www.the-jci.org/article.php?id=35308

'/>"/>

Contact: Karen Honey press_releases@the-jci.org 215-573-1850 Journal of Clinical Investigation Source:Eurekalert

0 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Blue Cross and Blue Shield of Illinois Announces 2007 Charitable Donations
2. GSK Charitable Support Valued at $564 Million in 2007
3. JCI online early table of contents: March 13, 2008
4. Implantable medical devices may expose patients to security, privacy risks; solutions suggested
5. Perrigo Company to Market Over-the-Counter Cetirizine Hydrochloride, Pseudoephedrine Hydrochloride Extended-Release Tablets
6. Perrigo Company Announces Initial Shipments of Store Brand Omeprazole Tablets
7. V8 V-Fusion(R) Takes an Exotic, Tasty Twist on Vegetable Juice
8. JCI online early table of contents: March 3, 2008
9. AXA Equitable Meets the Needs of Two People under One Life Insurance Policy
10. Nanomedicine system engineered to enhance therapeutic effects of injectable drugs
11. Nurses Convince Hospital to Return to Bargaining Table